YY1 has been shown to mediate the TRAIL-resistant phenotype in a prostate carcinoma cell line by direct binding and inactivation of the promoter of DR5, also known as TRAIL receptor 2 (TRAILR2), and inhibit its transcription. The gene discussed is TNFRSF10B; the disease is prostate carcinoma.